Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITDAEPS (Basic)EPS (Weighted Average and Diluted)Income towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Summit Therapeutics (SMMT) Interest Expenses (2024)

Summit Therapeutics' Interest Expenses history spans 1 years, with the latest figure at $9000.0 for Q4 2024.

  • For Q4 2024, Interest Expenses changed N/A year-over-year to $9000.0; the TTM value through Sep 2025 reached $9000.0, down 99.9%, while the annual FY2024 figure was $8.7 million, 47.23% down from the prior year.
  • Interest Expenses reached $9000.0 in Q4 2024 per SMMT's latest filing, down from $2.5 million in the prior quarter.
  • In the past five years, Interest Expenses ranged from a high of $3.1 million in Q1 2024 to a low of $9000.0 in Q4 2024.